Zacks Investment Management Zentalis Pharmaceuticals, Inc. Transaction History
Zacks Investment Management
- $10.5 Billion
- Q4 2024
A detailed history of Zacks Investment Management transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 22,340 shares of ZNTL stock, worth $54,286. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,340Holding current value
$54,286% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
68.4MCall Options Held
48.5KPut Options Held
89.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$33.9 Million2.05% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$11.7 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.48MShares$10.9 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$7.95 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$7.55 Million2.71% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $138M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...